Abstract
Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.
MeSH terms
-
Acute Coronary Syndrome / drug therapy*
-
Acute Coronary Syndrome / physiopathology
-
Adenosine / administration & dosage
-
Adenosine / analogs & derivatives*
-
Adenosine / pharmacology
-
Adenosine / therapeutic use
-
Aspirin / therapeutic use
-
Clopidogrel
-
Double-Blind Method
-
Female
-
Humans
-
Male
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Purinergic P2 Receptor Antagonists / administration & dosage
-
Purinergic P2 Receptor Antagonists / pharmacology
-
Purinergic P2 Receptor Antagonists / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Risk Assessment
-
Ticagrelor
-
Ticlopidine / analogs & derivatives
-
Ticlopidine / therapeutic use
-
Treatment Outcome
Substances
-
Platelet Aggregation Inhibitors
-
Purinergic P2 Receptor Antagonists
-
Clopidogrel
-
Ticagrelor
-
Adenosine
-
Ticlopidine
-
Aspirin